Drug Approval | March 21, 2022
USFDA approves Perrigo’s Nasonex
Nasonex is a registered trademark of Organon and is used by Perrigo and its affiliates under license
Nasonex is a registered trademark of Organon and is used by Perrigo and its affiliates under license
All of Us Research Program releases genomic data to researchers, combined with participant-generated data collected on Vibrent Health’s research platform
It is a point-of-care portable, battery-operated, IoT-enabled platform with a sample to result in less than 1 hour
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Manipal Hospitals partners with ConnectedLife, leveraging Fitbit wearable technology, for Continuity of Care Post-High-Risk Surgeries built with Google Cloud
The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
DASH enables non-laboratory personnel to insert a nasal swab specimen directly into our test cartridge and then load the cartridge into the DASH instrument, providing an accurate result in about 15 minutes
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
Subscribe To Our Newsletter & Stay Updated
